Net Loss per Share |
Net Loss per Share Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
|
2022 |
|
2021 |
|
2022 |
|
2021 |
Numerator: |
|
|
|
|
|
|
|
Net income (loss) attributable to common stockholders – basic |
$ |
(18,615) |
|
$ |
20,807 |
|
|
$ |
(58,102) |
|
|
$ |
(15,676) |
|
Change in fair value for warrant liability |
— |
|
(42) |
|
— |
|
— |
Interest to convertible notes |
— |
|
123 |
|
— |
|
— |
Loss on extinguishment of debt |
— |
|
865 |
|
— |
|
— |
Change in fair value of derivative liability |
— |
|
(475) |
|
— |
|
— |
Net income (loss) attributable to common stockholders – diluted |
$ |
(18,615) |
|
$ |
21,278 |
|
|
$ |
(58,102) |
|
|
$ |
(15,676) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominator: |
|
|
|
|
|
|
|
Weighted average common shares outstanding – basic |
144,117,273 |
|
119,745,196 |
|
143,522,555 |
|
47,772,253 |
Weighted average effect of potentially dilutive securities: |
|
|
|
|
|
|
|
Effect of potentially dilutive convertible preferred stock |
— |
|
14,065,012 |
|
— |
|
— |
Effect of potentially dilutive warrants |
— |
|
423,271 |
|
— |
|
— |
Effect of potentially dilutive stock options |
— |
|
19,696,440 |
|
— |
|
— |
Effect of potentially dilutive restricted stock units |
— |
|
6,517 |
|
— |
|
— |
Total potentially dilutive securities |
— |
|
34,191,240 |
|
— |
|
— |
Weighted average common shares outstanding — diluted |
144,117,273 |
|
153,936,436 |
|
143,522,555 |
|
47,772,253 |
Net income (loss) per share attributable to common stockholders - basic |
$ |
(0.13) |
|
$ |
0.17 |
|
$ |
(0.40) |
|
$ |
(0.33) |
Net income (loss) per share attributable to common stockholders - diluted |
$ |
(0.13) |
|
$ |
0.14 |
|
$ |
(0.40) |
|
$ |
(0.33) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The following potentially dilutive outstanding securities were excluded from the computation of diluted net loss per share attributable to common stockholders because their effect would have been anti-dilutive or issuance of such shares is contingent upon the satisfaction of certain conditions which were not satisfied by the end of the period:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended September 30, |
|
Nine Months Ended September 30, |
|
2022 |
|
2021 |
|
2022 |
|
2021 |
Options issued and outstanding |
21,027,840 |
|
1,589,357 |
|
|
21,027,840 |
|
21,285,797 |
|
Public Warrants to purchase common stock |
14,324,994 |
|
|
14,325,000 |
|
|
14,324,994 |
|
|
14,325,000 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants to purchase common stock (Finback)*** |
2,552,913 |
|
|
2,214,879 |
|
|
2,552,913 |
|
|
2,552,913 |
|
Unvested restricted stock units |
7,336,179 |
|
|
1,664,567 |
|
|
7,336,179 |
|
|
1,671,084 |
|
Unvested performance stock units |
889,000 |
|
|
— |
|
|
889,000 |
|
|
— |
|
Earn-out shares** |
15,000,000 |
|
|
15,000,000 |
|
|
15,000,000 |
|
|
15,000,000 |
|
Contingently issuable common stock** |
1,897,500 |
|
|
1,897,500 |
|
|
1,897,500 |
|
|
1,897,500 |
|
Convertible notes (as converted to common stock)* |
— |
|
|
5,408,672 |
|
|
— |
|
|
5,408,672 |
|
|
63,028,426 |
|
|
42,099,975 |
|
|
63,028,426 |
|
|
62,140,966 |
|
*Conversion feature is only triggered upon the closing of a Qualified Financing Event
**Issuance of Earn-out shares and Contingently issuable common stock are contingent upon the satisfaction of certain conditions, which were not satisfied by the end of the period
***Includes 700,575 vested warrants and 1,852,338 unvested warrants as of September 30, 2022
|